Datasheet

CDKN2A Antibody
CATALOG NUMBER: 4211

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:CDKN2A antibody can be used for detection of CDKN2A by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.

Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human and rat samples and Immunofluorescence in human and rat samples. All other applications and species not yet tested.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1411 - Mouse Colon Tissue Lysate
 2) Cat. No. 1320 - Human Colon Tissue Lysate
PREDICTED MOLECULAR WEIGHT:Predicted: 17 kDa

Observed: 20 kDa
IMMUNOGEN:CDKN2A antibody was raised against an 18 amino acid synthetic peptide from near the amino terminus of human CDKN2A.

The immunogen is located within the first 50 amino acids of CDKN2A.
HOST SPECIES:Rabbit

Properties

PURIFICATION:CDKN2A Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:CDKN2A Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:CDKN2A antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:CDKN2A Antibody: ARF, MLM, P14, P16, P19, CMM2, INK4, MTS1, TP16, CDK4I, CDKN2, INK4A, MTS-1, P14ARF, P19ARF, P16INK4, P16INK4A, P16-INK4A, Cyclin-dependent kinase 4 inhibitor A
ACCESSION NO.:NP_000068
PROTEIN GI NO.:4502749
OFFICIAL SYMBOL:CDKN2A
GENE ID:1029

Background

BACKGROUND:CDKN2A Antibody: The CDKN2A locus gives rise to 2 distinct transcripts from different promoters. The transcripts have been designated p16(INK4A) and p14(ARF). This chromosomal region undergoes a number of inversions, translocations, heterozygous deletions, and homozygous deletions in a variety of malignant cell lines including those from glioma, non-small cell lung cancer, leukemia, and melanoma. Deletion of the region containing CDKN2A is found in more than half of all melanoma cell lines. Conversely, transfection of CDKN2A suppressed the growth of two independent mesothelioma cell lines, suggesting that inactivation of the CDKN2 gene is an essential step in the etiology of malignant mesotheliomas. CDKN2A induces a G1 cell cycle arrest by inhibiting the phosphorylation of the Rb protein by the cyclin-dependent kinases CDK4 and CDK6. CDKN2A is expressed as at least three distinct isoforms.
REFERENCES: 1) Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the p16(MTS1) locus. Cancer Res. 1995; 55:2988-94.
2) Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 1994; 8:22-6.
3) Kratzke RA, Otterson GA, Lincoln CE, et al. Immunohistochemical analysis of the p16 (INK4) cyclin-dependent kinase inhibitor in malignant mesothelioma. J. Nat. Cancer Inst. 1995; 87:1870-5.
4) Stott FJ,; Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998; 17:5001-14.

For Research Use Only